

Insulin gives Denmark's Novo Nordisk a Q1 boost

May 1 2013

(AP)—Danish pharmaceutical company Novo Nordisk A/S says first-quarter net profit rose 28 percent on strong sales of its diabetic drugs.

The world's largest insulin maker said [net profit](#) in the first three months of 2013 was 5.9 million kroner (\$1 million), up from 4.7 million kroner. Revenue for the period came in at 20 billion kroner (\$3.5 billion), up 13 percent.

Chief Executive Lars Rebien Soerensen said Wednesday he was pleased by the strong insulin sales, and said the company expects to see sales grow between 9 and 11 percent this year and [operating profit](#) rising by around 10 percent.

The company's share price was up around 0.2 percent at 993 kroner in morning trading in Copenhagen.

© 2013 The Associated Press. All rights reserved.

Citation: Insulin gives Denmark's Novo Nordisk a Q1 boost (2013, May 1) retrieved 25 April 2024 from <https://medicalxpress.com/news/2013-05-insulin-denmark-novo-nordisk-q1.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.